Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Lipocine Inc (LPCN)

Lipocine Inc (LPCN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD) PR Newswire - Wed Feb 18, 7:00AM CST

SALT LAKE CITY , Feb. 18, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective...

LPCN : 9.43 (-0.74%)
Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) PR Newswire - Tue Jan 20, 7:00AM CST

SALT LAKE CITY , Jan. 20, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective...

LPCN : 9.43 (-0.74%)
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) PR Newswire - Mon Jan 12, 7:00AM CST

SALT LAKE CITY , Jan. 12, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective...

LPCN : 9.43 (-0.74%)
Biotech’s New Edge: 5 Companies Mastering "How" We Dose BayStreet.ca - Fri Jan 2, 10:31AM CST

ISSUED ON BEHALF OF DOSEOLOGY SCIENCES INC. VANCOUVER – Baystreet.ca News Commentary – Pharmaceutical markets are witnessing drug delivery devices surge toward $862.16 billion by 2034 as industry...

MOOD.CN : 0.5500 (unch)
WST : 245.38 (+0.47%)
PODD : 245.25 (-1.66%)
DOSEF : 0.5300 (-1.58%)
LPCN : 9.43 (-0.74%)
DARE : 1.6600 (unch)
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone PR Newswire - Tue Dec 16, 2025

SALT LAKE CITY , Dec. 16, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective...

LPCN : 9.43 (-0.74%)
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) PR Newswire - Tue Nov 18, 2025

SALT LAKE CITY , Nov. 18, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective...

LPCN : 9.43 (-0.74%)
Lipocine: Q3 Earnings Snapshot AP - Thu Nov 6, 2025

Lipocine: Q3 Earnings Snapshot

LPCN : 9.43 (-0.74%)
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025 PR Newswire - Thu Nov 6, 2025

SALT LAKE CITY , Nov. 6, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral...

LPCN : 9.43 (-0.74%)
Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek® PR Newswire - Tue Nov 4, 2025

SALT LAKE CITY , Nov. 4, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective...

LPCN : 9.43 (-0.74%)
Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD) PR Newswire - Tue Sep 30, 2025

One-Third of Patients Randomized; Topline Results Expected in 2Q 2026

LPCN : 9.43 (-0.74%)

Barchart Exclusives

This Blue-Chip Stock Just Slashed Its Dividend by 50%. Should You Run Away Now? Barchart - 59 minutes ago
LyondellBasell’s 50% dividend cut shocks income investors, but the move may signal balance-sheet defense rather than long-term weakness. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot